Statement: There were 4 cases of Febrile neutropenia in cohort 1 of the primary trial, and 0 cases of heart failure.
Primary_evidence: Adverse Events 1:   Total: 46/127 (36.22%)   Febrile neutropenia 4/127 (3.15%)   Neutropenia 1/127 (0.79%)   Atrial fibrillation 2/127 (1.57%)   Cardiac failure 0/127 (0.00%)   Left ventricular dysfunction 4/127 (3.15%)   Mitral valve disease 1/127 (0.79%)   Myocardial ischaemia 1/127 (0.79%)   Sinus tachycardia 1/127 (0.79%)   Myocardial infarction 1/127 (0.79%)   Adrenal haemorrhage 1/127 (0.79%) Adverse Events 2:   Total: 28/124 (22.58%)   Febrile neutropenia 2/124 (1.61%)   Neutropenia 1/124 (0.81%)   Atrial fibrillation 0/124 (0.00%)   Cardiac failure 1/124 (0.81%)   Left ventricular dysfunction 0/124 (0.00%)   Mitral valve disease 0/124 (0.00%)   Myocardial ischaemia 0/124 (0.00%)   Sinus tachycardia 0/124 (0.00%)   Myocardial infarction 0/124 (0.00%)   Adrenal haemorrhage 0/124 (0.00%)